← All organizations
Highest phase reached
Phase 4
First clinical trial
Mar 1, 2001First marketed drug
Apr 11, 2017First NDA
Apr 11, 2017Last known activity
Dec 31, 2025
Timeline
Drugs by trial phase (22 distinct, 68 trials)
Phase 4 (1 own, 0 via acquisition)
Phase 3 (5 own, 0 via acquisition)
Phase 2 (9 own, 0 via acquisition)
Phase 1 (7 own, 0 via acquisition)
Indications
Approved for
Studied for
- Adrenal Hyperplasia, Congenital
- Adrenocortical Hyperfunction
- Adrenogenital Syndrome
- Brain Diseases
- Breast Neoplasms
- Carcinoma, Renal Cell
- Central Nervous System Neoplasms
- Chorea
- Depression
- Depressive Disorder
- Diabetes Mellitus
- Diabetes Mellitus, Type 1
- Dyskinesias
- Epilepsy
- Glioblastoma
- Hepatic Insufficiency
- Huntington Disease
- Hyperplasia
- Kidney Neoplasms
- Liver Failure
- Lung Neoplasms
- Multiple Sclerosis
- Nervous System Neoplasms
- Parkinson Disease
- Psychotic Disorders
- Schizophrenia
- Sclerosis
- Sleep Initiation and Maintenance Disorders
- Substance Withdrawal Syndrome
- Syndrome
- Tardive Dyskinesia
- Tourette Syndrome
Marketed drugs (3)
Recent trials (50)
- NCT07288320OfficialPhase 2Dec 31, 2025
- NCT07227818Lead sponsorPhase 3Dec 31, 2025
- NCT07227818OfficialPhase 3Dec 31, 2025
- NCT07288320Lead sponsorPhase 2Dec 31, 2025
- NCT07288333Lead sponsorPhase 2Dec 31, 2025
- NCT07288333OfficialPhase 2Dec 31, 2025
- NCT07111988CollaboratorPhase 2Oct 31, 2025
- NCT07187375Lead sponsorPhase 2Sep 30, 2025
- NCT07105111OfficialPhase 4Aug 29, 2025
- NCT07105111Lead sponsorPhase 4Aug 29, 2025
- NCT07196501OfficialPhase 3Aug 18, 2025
- NCT07196501Lead sponsorPhase 3Aug 18, 2025
- NCT07105098OfficialPhase 3Aug 11, 2025
- NCT07105098Lead sponsorPhase 3Aug 11, 2025
- NCT07114874Lead sponsorPhase 3Jul 11, 2025
Details
- Founded
- San Diego, CA, US Jul 1, 1992
- First NDA
- Apr 11, 2017
- Last known activity
- Dec 31, 2025
Designations held
- Orphan drug
- Fast track
- Priority review
- Breakthrough therapy